Involvement of Mrp2 (Abcc2) in biliary excretion of moxifloxacin and its metabolites in the isolated perfused rat liver

Journal of Pharmacy and Pharmacology

Volumn 60, Issue 1, 2008, Pages 55-62

  Ahmed, Salwa ^a   Vo, Nha T P ^a   Thalhammer, Theresia ^b   Thalhammer, Florian ^b   Gattringer, Klaus Bernhard ^b   Jäger, Walter ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BROMSULFOPHTHALEIN; DRUG METABOLITE; GLUCURONIDE; MOXIFLOXACIN; MULTIDRUG RESISTANCE PROTEIN 2; SULFATE;

ANIMAL EXPERIMENT; ARTICLE; BILE FLOW; BILIARY EXCRETION; CONJUGATE; CONTROLLED STUDY; DRUG BILE LEVEL; DRUG COMPETITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG TRANSPORT; EFFUSION; EXTRACTION; ISOLATED LIVER; LIVER CLEARANCE; LIVER PERFUSION; MALE; METABOLITE; NONHUMAN; RAT; RAT STRAIN; WISTAR RAT;

ALGORITHMS; ANIMALS; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BILE; BIOLOGICAL AVAILABILITY; GLUCURONIDES; LIVER; MALE; MEMBRANE TRANSPORT PROTEINS; METABOLIC CLEARANCE RATE; MOLECULAR STRUCTURE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PERFUSION; QUINOLINES; RATS; RATS, MUTANT STRAINS; RATS, WISTAR; SULFATES;

EID: 38349126398     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.60.1.0007     Document Type: Article

References (34)

1. Aleman, A. M., Quirce, S., Cuesta, J., Novalbos, A., Sastre, J. (2002) Anaphylactoid reaction caused by moxifloxacin. J. Investig. Allergol. Clin. Immunol. 12: 67-68
2. Andersson, M. I., MacGowan, A. P. (2003) Development of the quinolones. J. Antimicrob. Chemother. 51: 1-11
3. Bailey, M. J., Dickinson, R. G. (2003) Acyl glucuronide reactivity in perspective: biological consequences. Chem-Biol. Interact. 145: 117-137
4. Ball, P. (2003) Adverse drug reactions: implications for the development of fluoroquinolones. J. Antimicrob. Chemother. 51: 21-27
5. Boyer, J. L., Klatskin, G. (1970) Canalicular bile flow and bile secretory pressure. Evidence for a non-bile salt dependent fraction in the isolated perfused rat liver. Gastroenterology 59: 853-859
6. Chandra, P., Brouwer, K. L. (2004) The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm. Res. 21: 719-735
7. Chu, X., Huskey, S. W., Braun, M. P., Sarkadi, B., Evans, D. C., Evers, R. (2004) Transport of ethinylestradiol glucuronide and ethinylestradiol sulfate by the multidrug resistance proteins MRP1, MRP2 and MRP3. J. Pharmacol. Exp. Ther. 309: 156-164
8. Elferink, R. O., Groen, A. K. (2002) Genetic defects in hepatobiliary transport. Biochim. Biophys. Acta. 1586: 129-145
9. Fuhrmann, V., Schenk, P., Jaeger, W., Ahmed, S., Thalhammer, F. (2004) Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. J. Antimicrob. Chemother. 54: 780-784
10. Graf, J. (1983) Canalicular bile salt-independent bile formation: concepts and clues from electrolyte transport in rat liver. Am. J. Physiol. 244: 233-246
11. Ho, D. Y., Song, J. C., Wang, C. C. (2003) Anaphylactoid reaction to ciprofloxacin. Ann. Pharmacother. 37: 1018-1023
12. Jäger, W., Winter, O., Halper, B., Salamon, A., Satori, M., Gajdzik, L., Hamilton, G., Theyer, G., Graf, J., Thalhammer, T. (1997) Modulation of liver canicular transport processes by the tyrosine kinase inhibitor genistein: implication of genistein metabolites in rats. Hepatology 26: 1467-1476
13. Jansen, P. L., Peters, W. H., Lamers, W. H. (1985) Hereditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport. Hepatology 4: 573-579
14. -) rats: relation to the pathogenesis of black liver in the Dubin-Johnson syndrome and Corriedale sheep with an analogous excretory defect. Hepatology 15: 1154-1159
15. Maliepaard, M., Scheffer, G. L., Faneyte, I. F., van Gastelen, M. A., Pijnenborg, A. C., Schinkel, A. H., van de Vijver M. J., Scheper, R. J., Schellens, J. H. (2001) Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61: 3458-3464
16. Michot, J. M., Seral, C., van Bambeke, F., Mingeot-Leclercq, M. P., Tulker, P. M. (2005) Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, gerenoxacin, and moxifloxacin) in J774 macrophages. Antimicrob. Agents Chemother. 49: 2429-2437
17. Mizuno, N., Niwa, T., Yotsumoto, Y., Sugiyama, Y. (2003) Impact of drug transporter studies on drug discovery and development. Pharmacol. Rev. 55: 425-461
18. Muijsers, R. B., Jarvis, B. (2002) Moxifloxacin in uncomplicated skin and skin structure infections. Drugs 62: 967-973
19. Oliphant, C. M., Green, G. M. (2002) Quinolones: a comprehensive review. Am. Fam. Phys. 65: 455-464
20. Pestova, E., Millichap, J. J., Noskin, G. A. (2000) Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J. Antimicrob. Chemother. 45: 583-590
21. Rouveix, B. (2007) Clinical implications of multiple drug resistance efflux pumps of pathogenic bacteria. J. Antimicrob. Chemother. 29: 1208-1209
22. Sachs, B., Riegel, S., Seebeck, J., Beier, R., Schichler, D., Barger, A., Merk, H. F., Erdmann, S. (2006) Fluoroquinolone-associated anaphylaxis in spontaneous adverse drug reaction reports in Germany: differences in reporting rates between individual fluoroquinolones and occurrence after first-ever use. Drug Saf. 29: 1087-1100
23. Sasabe, H., Kato, Y., Tsuji, A., Sugiyama, Y. (1998) Stereoselective hepatobiliary transport of the quinolone antibiotic grepafloxacin and its glucuronide in the rat. J. Pharmacol. Exp. Ther. 284: 661-668
24. Schwab, D., Grauer, M., Hahn, E. G., Mühldorfer, S. (2005) Biliary secretion of moxifloxacin in obstructive cholangitis and the non-obstructed biliary tract. Aliment. Pharmacol. Ther. 22: 417-422
25. Shipkova, M., Armstrong, V. W., Oellerich, M., Wieland, E. (2003) Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther. Drug. Monit. 25: 1-16
26. Stass, H., Kubitza, D. (1999) Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob. Chemother. 43: 83-90
27. Stass, H., Kubitza, D. (2001a) Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline. Clin. Pharmacokinet. 40: 63-70
28. Stass, H., Kubitza, D. (2001b) Profile of moxifloxacin drug interactions. Clin. Infect. Dis. 32: 47-50
29. Stass, H., Dalhoff, A., Kubitza, D., Schühly, U. (1998) Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob. Agents. Chemother. 42: 2060-2065
30. Tachibana, M., Tanaka, M., Masubuchi, Y., Horie, T. (2005) Acyl glucuronidation of fluoroquinolone antibiotics by the UDP- glucuronosyltransferase 1A subfamily in human liver microsomes. Drug Metab. Dispos. 33: 803-811
31. Takenaka, O., Horie, T., Suzuki, H., Sugiyama, Y. (1995) Different biliary excretion systems for glucuronide and sulfate of a model compound; study using Eisai hyperbilirubinemic rats. J. Pharmacol. Exp. Ther. 274: 1362-1369
32. Woodcock, J. M., Andrews, J. M., Boswell, F. J., Brenwald, N. P., Wise, R. (1997) In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob. Agents Chemother. 41: 101-106
33. Yagi, Y., Shibutani, S., Hodoshima, N., Ishiwata, K., Okudaira, N., Li, Q., Sai, Y., Kato, Y., Tsuji, A. (2003) Involvement of multiple transport systems in the disposition of an active metabolite of a prodrug-type new quinolone antibiotic, prulifloxacin. Drug Metab. Pharmacokinet. 18: 381-389
34. Zamek-Gliszczynski, M. J., Hoffmaster, K. A., Tian, X., Zhao, R., Polli, J. W., Humphreys, J. E., Webster, L. O., Bridges, A. S., Kalvass, J. C., Brouwer, K. L. (2005) Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1. Drug Metab. Dispos. 33: 1158-1165